CEL-SCI : Un peu de lecture

labla21

07 février 2012 •08:22

http://seekingalpha.com/article/343151-2-biotechs-on-teva-s-radar-screen

labla21

07 février 2012 •08:36

mr FoSco :-))

labla21

07 février 2012 •08:39

"So long as these biotechs keep performing and meeting key milestones, their shares should continue to appreciate in value"

FoscoS

07 février 2012 •11:24

oui, mais l'analyse était payante avant, et elle est devenue gratuite (ou accessible ?) depuis peu... ;-)

FoscoS

07 février 2012 •11:29

http://seekingalpha.com/article/344141-teva-invests-in-immuno-therapy-for-deadly -cancer-research?source=yahoo

mais bon, se méfier des blogs où tout le monde peut écrire

labla21

07 février 2012 •11:38

A - de 5 Doll. c'est du vole ;-)

FoscoS

07 février 2012 •13:35

il y du vrai. Quand tu penses que Nicox a été jusqu'à 1Md de Capi sans produit en ph III ...
La spécu n'est pas toujours au RDV... quoiqu'on est peut être en train de rattraper cette anomalie.

byscotte

07 février 2012 •15:03

Faut qu'elle arrête sinon je vais replonger !

Allez , faut qu'j'aille faire du bois ! pfff

:-)

SIMlS

07 février 2012 •16:20

Finally, CEL-SCI Corporation has been off the trading radar for a couple of years now, but something struck a chord with the market yesterday, as CVM was one of the most-talked about and traded tickers within the small cap realm. What was the buzz from this cancer vaccine developer (a buzz that's still gong string today - the stocks up 11%)? One of the possibilities is that Teva wants a piece of what CEL-SCI has been working on for years.... a drug called Multikine, for the treatment of head and neck tumors.

Thing is, the TEVA/CVM relationship isn't exactly a new one. Teva Pharmaceuticals has been a supporter/sponsor of Multikine for a while; that buzz was just rekindled a couple of fays ago. Perhaps just as compelling are early reports - ok, rumors - that Phase III testing is (so far) going well, meaning the cancer vaccines does indeed seem to be working at least a little better than the alternative. It's not hard to believe either. Although CEL-SCI Corporation has taken a while to get here, the underlying vaccine technology has shown promising Phase I and Phase II results, and other companies are successfully using the same idea for other cancer indications.

The drug working or not, CVM shares have made a nice technical reversal that has since been supported. The initial surge of the breakout effort came in the first week of January when shares popped above the 100-day moving average line (gray) for the first times in months. Though the stock couldn't hang onto all of that gain then, the pullback was halted and reversed at the 100-day line again, which was used as a springboard for this week's revival. Though CEL-SCI Corporation still needs to find a sustainable pace, with the 50-day average knocking on the door of crossing above the 100-day line, it's hard to say that the technical momentum isn't aligning with the company's impressive underlying R&D progress.


source :
http://www.smallcapnetwork.com/Biotech-Roundup-What-Now-for-Peregrine-PPHM-BioSa nte-BPAX-and-CEL-SCI-CVM/s/via/1789/article/view/p/mid/1/id/117/